182 related articles for article (PubMed ID: 38662778)
1. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
2. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
4. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
[TBL] [Abstract][Full Text] [Related]
5. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
8. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
11. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
[TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.
Anfuso B; Tiribelli C; Adorini L; Rosso N
Sci Rep; 2020 Feb; 10(1):1699. PubMed ID: 32015483
[TBL] [Abstract][Full Text] [Related]
13. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
14. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
[TBL] [Abstract][Full Text] [Related]
15. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
Rodrigues PM; Afonso MB; Simão AL; Carvalho CC; Trindade A; Duarte A; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM; Castro RE
Cell Death Dis; 2017 Apr; 8(4):e2748. PubMed ID: 28406477
[TBL] [Abstract][Full Text] [Related]
16. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Vignozzi L; Filippi S; Comeglio P; Cellai I; Sarchielli E; Morelli A; Rastrelli G; Maneschi E; Galli A; Vannelli GB; Saad F; Mannucci E; Adorini L; Maggi M
Mol Cell Endocrinol; 2014 Mar; 384(1-2):143-54. PubMed ID: 24486698
[TBL] [Abstract][Full Text] [Related]
20. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
